A Total of 11 Poster Presentations Will Be
Presented, Including Data from Two Pivotal Phase 3 Trials and
12-Month Safety Extension Trial of MIEBO™ (Perfluorohexyloctane
Ophthalmic Solution)
Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a
leading global eye health company dedicated to helping people see
better to live better, today announced that researchers will
present the results of 11 scientific poster presentations involving
the company’s consumer, vision care and pharmaceutical products
during the American Optometric Association (AOA) Optometry’s
Meeting e-posters Virtual Event, which is taking place from June
13-14, 2023. In addition, the company will host several sponsored
education events at the Optometry’s Meeting in Washington, D.C.
from June 21-24, 2023.
The poster presentations will include data from the two pivotal
Phase 3 trials, GOBI and MOJAVE, and 12-month KALAHARI safety
extension study of MIEBO™ (perfluorohexyloctane ophthalmic
solution). MIEBO was approved by the U.S. Food and Drug
Administration on May 18, 2023, for the treatment of the signs and
symptoms of dry eye disease (DED). It is the first and only FDA
approved prescription eye drop that directly targets tear
evaporation in individuals with DED. Three posters will highlight
the benefits of new Biotrue® Hydration Boost Contact Lens
Rehydrating Drops, and two others will feature new data on our
recently launched Bausch + Lomb INFUSE® Multifocal silicone
hydrogel (SiHy) daily disposable contact lenses designed for
presbyopic patients: a comparison of the power profiles across the
near, intermediate and distance vision zones and an eye care
practitioner fitting assessment of the lens.
“Bausch + Lomb is committed to investing in, and bringing to
market, new innovations that help eye care practitioners meet the
evolving vision needs of their patients,” said Yehia Hashad, M.D.,
executive vice president, Research & Development and chief
medical officer, Bausch + Lomb. “We will share some of these new
innovations, including MIEBO, Biotrue Hydration Boost for Contacts
and Bausch + Lomb INFUSE Multifocal lenses, with attendees during
the Optometry’s Meeting. We also look forward to presenting a
variety of new data on these products and some of our other
consumer and pharmaceutical products, as well as hosting attendees
at our education events.”
The complete list of scientific e-poster presentations, as well
as details for the featured education events, is as follows:
E-Poster Presentations
- “A New Preservative-free Lubricating and Rewetting drop with
Antioxidant Erythritol Protects Hyaluronan (HA) from Free
Radicals.” Siverling et al.
- “Clinical Evaluation of the Safety and Tolerability of Lumify
Eye Illuminations™ (LEI) Cosmetic Products.” Wesley et al.
- “Clinical Performance of Unique Preservative Free Contact Lens
Lubricating and Rewetting Drop.” Shafer et al.
- “Contemporary Progressive Daily Disposable Silicone Hydrogel
Multifocal Contact Lenses: A Comparison of Power Profiles Across
Near, Intermediate and Distance Zones.” Reindel et al.
- “Cumulative Irritation Testing and Repeated Insult Patch
Testing with Lumify Eye Illuminations™ (LEI) Cosmetic Products.”
Wesley et al.
- “Hyaluronan (HA) from a new preservative-free lubricating and
rewetting drop is retained and released by conventional and
silicone hydrogel contact lenses.” Scheuer et al.
- “Latanoprostene bunod 0.024% in patients switched from prior
pharmacotherapy: a multicenter retrospective chart review.” Cothran
et al.
- “Long-term Safety and Efficacy of NOV03 (Perfluorohexyloctane)
for the Treatment of Patients with Dry Eye Disease Associated with
Meibomian Gland Dysfunction: the KALAHARI Study.” Evans et al.
- “Perfluorohexyloctane (NOV03) for Dry Eye Disease Associated
with Meibomian Gland Dysfunction: In Vitro Inhibition of
Evaporation.” Vollmer et al.
- “Perfluorohexyloctane (NOV03) for Dry Eye Disease Associated
with Meibomian Gland Dysfunction: Pooled Analysis of GOBI and
MOJAVE Studies.” Fahmy et al.
- “Practitioner Assessment of Fitting a Novel Silicone Hydrogel
Daily Disposable Multifocal Contact Lens.” Rah et al.
Featured Education Events
Wednesday, June 21
- “Showcasing Inflammation and IOP Control” 7:00 p.m. ET at Del
Frisco’s (950 St. NW, Suite 501, Washington, DC) Derek Cunningham,
O.D., and Justin Schweitzer, O.D., will discuss the benefits of
using LOTEMAX® SM (loteprednol etabonate ophthalmic gel), 0.38%,
and VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%.
Register in advance at
https://na.eventscloud.com/website/54916/.
Thursday, June 22
- “Eyeing Up Evaporation: Getting at the Heart of Dry Eye
Disease” 8:00-9:00 a.m. ET in Room #207B (level 2) in the Walter E.
Washington Convention Center Jade Coats, O.D., and James Deom,
O.D., will discuss current thinking on the role of evaporation in
DED, reviewing causative factors, DED pathophysiology, diagnostic
approaches and current treatments.
- “Believe in the Power of Multifocals: Introducing Bausch + Lomb
INFUSE® Multifocal” 12:00-1:00 p.m. ET in Room #207B (level 2) in
the Walter E. Washington Convention Center Mile Brujic, O.D., and
Paul Karpecki, O.D., will lead a conversation on the new Bausch +
Lomb INFUSE® Multifocal contact lenses, which were designed to
directly address the common problems that presbyopic patients
experience with multifocal lenses, including contact lens
dryness.
- “All Eyes on Evaporation” 7:00 p.m. ET at Mastro’s Steakhouse
(600 13th St NW, Washington, DC) Melissa Barnett, O.D., and Paul
Karpecki, O.D., will discuss current thinking on the role of
evaporation in DED. Reviewing causative factors, DED
pathophysiology diagnostic approaches and current treatments.
Register in advance:
https://na.eventscloud.com/website/54915/.
Friday, June 23
- “Showcasing Inflammation and IOP Control” 8:00-9:00 a.m. ET in
Room #207A (level 2) in the Walter E. Washington Convention Center
Nora Cothran, O.D., and Jessica Steen, O.D., will discuss two of
the company's pharmaceutical advancements: LOTEMAX® SM (loteprednol
etabonate ophthalmic gel), 0.38%, and VYZULTA® (latanoprostene
bunod ophthalmic solution), 0.024%.
- “Bausch + Lomb Practice Pearls & Innovative Products”
12:00-1:00 p.m. ET in Room #207A (level 2) in the Walter E.
Washington Convention Center Ben Gaddie, O.D., and Mile Brujic,
O.D., FAAO will share practical patient cases using products from
across the Bausch + Lomb consumer, vision care and pharmaceutical
portfolios.
Important Safety Information for MIEBO
INDICATION MIEBO™ (perfluorohexyloctane ophthalmic
solution) is used to treat the signs and symptoms of dry eye
disease.
IMPORTANT SAFETY INFORMATION
- Patients should remove contact lenses before using MIEBO™ and
wait for at least 30 minutes before reinserting.
- It is important for patients to use MIEBO exactly as
prescribed.
- It is not known if MIEBO™ is safe and effective in children
under the age of 18.
- The most common eye side effect seen in studies was blurred
vision (1% to 3 % of patients reported blurred vision and eye
redness).
Click here for full Prescribing Information for
MIEBO.
Important Safety Information for LOTEMAX SM
INDICATION LOTEMAX SM (loteprednol etabonate ophthalmic
gel) 0.38% is a corticosteroid indicated for the treatment of
post-operative inflammation and pain following ocular surgery.
IMPORTANT SAFETY INFORMATION
- LOTEMAX SM, as with other ophthalmic corticosteroids, is
contraindicated in most viral diseases of the cornea and
conjunctiva including epithelial herpes simplex keratitis
(dendritic keratitis), vaccinia, and varicella, and also in
mycobacterial infection of the eye and fungal diseases of ocular
structures.
- Prolonged use of corticosteroids may result in glaucoma with
damage to the optic nerve, defects in visual acuity and fields of
vision. Steroids should be used with caution in the presence of
glaucoma. If LOTEMAX SM is used for 10 days or longer, IOP should
be monitored.
- Use of corticosteroids may result in posterior subcapsular
cataract formation.
- The use of steroids after cataract surgery may delay healing
and increase the incidence of bleb formation. In those with
diseases causing thinning of the cornea or sclera, perforations
have been known to occur with the use of topical steroids. The
initial prescription and renewal of the medication order should be
made by a physician only after examination of the patient with the
aid of magnification such as slit lamp biomicroscopy and, where
appropriate, fluorescein staining.
- Prolonged use of corticosteroids may suppress the host response
and thus increase the hazard of secondary ocular infections. In
acute purulent conditions, steroids may mask infection or enhance
existing infections.
- Employment of a corticosteroid medication in the treatment of
patients with a history of herpes simplex requires great caution.
Use of ocular steroids may prolong the course and may exacerbate
the severity of many viral infections of the eye (including herpes
simplex).
- Fungal infections of the cornea are particularly prone to
develop coincidentally with long-term local steroid application.
Fungus invasion must be considered in any persistent corneal
ulceration where a steroid has been used or is in use. Fungal
cultures should be taken when appropriate.
- Contact lenses should not be worn when the eyes are
inflamed.
- There were no treatment-emergent adverse drug reactions that
occurred in more than 1% of subjects in the three times daily group
compared to vehicle.
Click here for full Prescribing Information for
LOTEMAX SM.
Important Safety Information for VYZULTA
INDICATION VYZULTA (latanoprostene bunod ophthalmic
solution), 0.024% is indicated for the reduction of intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension.
IMPORTANT SAFETY INFORMATION
- Increased pigmentation of the iris and periorbital tissue
(eyelid) can occur. Iris pigmentation is likely to be
permanent
- Gradual changes to eyelashes, including increased length,
increased thickness, and number of eyelashes, may occur. These
changes are usually reversible upon treatment discontinuation
- Use with caution in patients with a history of intraocular
inflammation (iritis/uveitis). VYZULTA should generally not be used
in patients with active intraocular inflammation
- Macular edema, including cystoid macular edema, has been
reported during treatment with prostaglandin analogs. Use with
caution in aphakic patients, in pseudophakic patients with a torn
posterior lens capsule, or in patients with known risk factors for
macular edema
- There have been reports of bacterial keratitis associated with
the use of multiple-dose containers of topical ophthalmic products
that were inadvertently contaminated by patients
- Contact lenses should be removed prior to the administration of
VYZULTA and may be reinserted 15 minutes after administration
- Most common ocular adverse reactions with incidence ≥2% are
conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%),
and instillation site pain (2%)
Please click here for full Prescribing
Information.
Patients are encouraged to report negative side effects of
these prescription drugs to the FDA. Visit
www.fda.gov/medwatch or call 1-800-FDA-1088.
About Bausch + Lomb Bausch + Lomb is dedicated to
protecting and enhancing the gift of sight for millions of people
around the world – from the moment of birth through every phase of
life. Its comprehensive portfolio of more than 400 products
includes contact lenses, lens care products, eye care products,
ophthalmic pharmaceuticals, over-the-counter products and
ophthalmic surgical devices and instruments. Founded in 1853,
Bausch + Lomb has a significant global research and development,
manufacturing and commercial footprint with approximately 13,000
employees and a presence in nearly 100 countries. Bausch + Lomb is
headquartered in Vaughan, Ontario with corporate offices in
Bridgewater, New Jersey. For more information, visit www.bausch.com
and connect with us on Twitter, LinkedIn, Facebook and
Instagram.
Forward-looking Statements This news release may contain
forward-looking statements, which may generally be identified by
the use of the words “anticipates,” “hopes,” “expects,” “intends,”
“plans,” “should,” “could,” “would,” “may,” “believes,”
“estimates,” “potential,” “target,” or “continue” and variations or
similar expressions. These statements are based upon the current
expectations and beliefs of management and are subject to certain
risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include, but are not limited to, the
risks and uncertainties discussed in Bausch + Lomb’s filings with
the U.S. Securities and Exchange Commission and the Canadian
Securities Administrators, which factors are incorporated herein by
reference. They also include, but are not limited to, risks and
uncertainties caused by or relating to the evolving COVID-19
pandemic, and the fear of that pandemic and its potential effects,
the severity, duration and future impact of which are highly
uncertain and cannot be predicted, and which may have a material
adverse impact on Bausch + Lomb, including but not limited to its
project development timelines, launches and costs (which may
increase). Readers are cautioned not to place undue reliance on any
of these forward-looking statements. These forward-looking
statements speak only as of the date hereof. Bausch + Lomb
undertakes no obligation to update any of these forward-looking
statements to reflect events or circumstances after the date of
this news release or to reflect actual outcomes, unless required by
law.
© 2023 Bausch + Lomb. MTB.0157.USA.23
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230608005214/en/
Investors: Allison Ryan allison.ryan@bausch.com (877)
354-3705 (toll free) (908) 927-0735
Media: Lainie Keller lainie.keller@bausch.com (908)
927-1198
Kristy Marks kristy.marks@bausch.com (908) 927-0683
Bausch plus Lomb (NYSE:BLCO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bausch plus Lomb (NYSE:BLCO)
Historical Stock Chart
From Jul 2023 to Jul 2024